在这里,我们介绍了第一次人体研究的初步结果,以评估用锆- 89标记的atezolizumab (抗PD - L1 )成像的可行性,包括生物分布,然后测试其预测对PD - L1阻断反应的潜力( ClinicalTrials.gov标识符NCT 02453984和NCT 02478099 )。在阿替唑单抗治疗开始前,我们对22名患者进行了三种肿瘤类型的成像。PET信号是示踪剂暴露和...
Zr89-Atezo示踪剂的摄入可能会成为评估atezolizumab临床疗效,包括PFS和OS的较强预测标志,未来需要大样本研究并结合其他临床数据来进一步确认。
89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer.Programmed cell death protein-1/ligand-1 (PD-1/PD-L1) blockade is effective in a subset of patients with several tumor types, but predicting patient benefit using approved diagnostics ...
89Zr-atezolizumab uptake also increased slightly bonemarrow over time. his uptake consideredspeciic ree89 Zr, compactbone stableover time, tracerremained intact serum(Fig. 1a SupplementaryFig. 3a,b). Non-malignant lymph nodes were also visualized 89Zr-atezolizumab PE (Fig.1b). reportsabout 89 ...
PD-L1 detection using 89Zr-atezolizumab immuno-PET in renal cell carcinoma tumorgrafts from a patient with favorable nivolumab responseKidney cancer, Renal cancer, Immuno-PET, PD-L1, PD-1, PDX, Patient-derived xenograft, IO, Immunotherapy, Immune checkpoint inhibitors, Predictive biomarkers, SABR,...
et al. 89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. Nat Med 24, 1852–1858 (2018). https://doi.org/10.1038/s41591-018-0255-8 Download citation Received09 March 2018 Accepted10 September 2018 Published26 November 2018 Issue ...